Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
A phase III trial has demonstrated that in advanced non-small cell lung cancer (NSCLC)
cisplatin/ pemetrexed provides similar efficacy with better tolerability and more convenient
administration than cisplatin/gemcitabine. Moreover,this trial showed survival differences
based on histologic type. The investigators want to research some biomarkers that can predict
clinical outcomes.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
BB 1101 Cisplatin Dexamethasone Dexamethasone 21-phosphate Dexamethasone acetate Folic Acid Gemcitabine Hydroxocobalamin Pemetrexed Vitamin B 12 Vitamin B Complex Vitamins